BRPI0817954B8 - uso do 5-hidroxi-2-hidroximetil-y-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea - Google Patents

uso do 5-hidroxi-2-hidroximetil-y-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea

Info

Publication number
BRPI0817954B8
BRPI0817954B8 BRPI0817954A BRPI0817954A BRPI0817954B8 BR PI0817954 B8 BRPI0817954 B8 BR PI0817954B8 BR PI0817954 A BRPI0817954 A BR PI0817954A BR PI0817954 A BRPI0817954 A BR PI0817954A BR PI0817954 B8 BRPI0817954 B8 BR PI0817954B8
Authority
BR
Brazil
Prior art keywords
combat
hmp
increased
pyrone
hydroxymethyl
Prior art date
Application number
BRPI0817954A
Other languages
English (en)
Inventor
Silva Santos Alberdan
Paula Drumond Rodrigues Ana
Sérgio Costa Carvalho Antônio
Naum Alves Cláudio
Oliveira Da Silva Edilene
Luiz Martins Do Nascimento José
Original Assignee
Univ Federal Para
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Federal Para filed Critical Univ Federal Para
Priority to BRPI0817954A priority Critical patent/BRPI0817954B8/pt
Priority to AP2011005596A priority patent/AP3203A/xx
Priority to EP09806250.8A priority patent/EP2337560B1/en
Priority to US13/058,899 priority patent/US9115106B2/en
Priority to PCT/BR2009/000254 priority patent/WO2010017613A1/en
Publication of BRPI0817954A2 publication Critical patent/BRPI0817954A2/pt
Priority to ZA2011/01706A priority patent/ZA201101706B/en
Publication of BRPI0817954B1 publication Critical patent/BRPI0817954B1/pt
Publication of BRPI0817954B8 publication Critical patent/BRPI0817954B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

uso do 5-hidroxi-2-hidroximetil-(gama)-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea a presente patente refere-se a utilização do hmp (um metabólito secundário produzido por fungo filamentoso), como agente de estimulação da atividade microbicida do macrófago para atuação no combate da leishmaniose cutânea (lc) causada pelo protozoário leishmania (leishmania) amazonensis. o principal mecanismo de ação foi a ativação da atividade microbicida destas células hospedeiras através do aumento da produção de radicais de oxigênio, aumento da quantidade de lisossomos, aumento dos filamentos de actina e microtúbulos, e do aumento do espraiamento característico do estado de ativação dessas células, eliminando o agente da infecção. neste sentido a busca de moléculas de fácil obtenção e que não dependam de sazonalidade, além de apresentarem um mecanismo eficiente de combate e que não cause reações adversas é apresentado pelo hmp, um candidato potencial para uso no combate a lc na concentração mínima de 50 (mi)g/ml. portanto, o resultado apresentou alta atividade leishmanicida, que qualifica o uso do hmp como um potente candidato ao combate da leshmaniose cutânea.
BRPI0817954A 2008-08-14 2008-08-14 uso do 5-hidroxi-2-hidroximetil-y-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea BRPI0817954B8 (pt)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0817954A BRPI0817954B8 (pt) 2008-08-14 2008-08-14 uso do 5-hidroxi-2-hidroximetil-y-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea
AP2011005596A AP3203A (en) 2008-08-14 2008-08-14 Use of 5-hydroxy-2-hydroxymethyl-y-pyrone (HMP) asa leishmanicidal agent
EP09806250.8A EP2337560B1 (en) 2008-08-14 2009-08-14 Use of 5-hydroxy-2-hydroxymethyl- y -pyrone (hmp) as a leishmanicidal agent
US13/058,899 US9115106B2 (en) 2008-08-14 2009-08-14 Use of 5-hydroxy-2-hydroxymethyl-γ-pyrone (HMP) as a leishmanicidal agent
PCT/BR2009/000254 WO2010017613A1 (en) 2008-08-14 2009-08-14 Use of 5-hydroxy-2-hydroxymethyl- y -pyrone (hmp) as a leishmanicidal agent
ZA2011/01706A ZA201101706B (en) 2008-08-14 2011-03-04 Use of 5-hydroxy-2-hydroxymethyl-y-pyrone(hmp)as a leishmanicidal agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0817954A BRPI0817954B8 (pt) 2008-08-14 2008-08-14 uso do 5-hidroxi-2-hidroximetil-y-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea

Publications (3)

Publication Number Publication Date
BRPI0817954A2 BRPI0817954A2 (pt) 2011-01-11
BRPI0817954B1 BRPI0817954B1 (pt) 2019-08-06
BRPI0817954B8 true BRPI0817954B8 (pt) 2021-05-25

Family

ID=43417160

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817954A BRPI0817954B8 (pt) 2008-08-14 2008-08-14 uso do 5-hidroxi-2-hidroximetil-y-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea

Country Status (6)

Country Link
US (1) US9115106B2 (pt)
EP (1) EP2337560B1 (pt)
AP (1) AP3203A (pt)
BR (1) BRPI0817954B8 (pt)
WO (1) WO2010017613A1 (pt)
ZA (1) ZA201101706B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2735339B1 (en) * 2012-11-27 2014-10-22 King Saud University Extract and isolated compounds from Drechslera rostrata and/or Eurotium tonophilum for use as anti-leishmania-major agents
US9168268B1 (en) * 2013-04-09 2015-10-27 Universidad De Antioquia Saponins and chromans derivatives mixture compositions against leishmaniasis, Trypanosomiasis americana, malaria, Trypanosomiasis africana and Fasciola hepatica

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2616328B1 (fr) * 1987-06-12 1990-03-02 Moet Hennessy Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de murier, ou au moins une flavone, en particulier une kuwanone et composition pharmaceutique, notamment dermatologique, a activite depigmentante, ou anti-inflammatoire, ou cosmetique, l'incorporant
GB0421911D0 (en) * 2004-10-01 2004-11-03 Univ Cambridge Tech Methods and means

Also Published As

Publication number Publication date
AP3203A (en) 2015-03-31
EP2337560A4 (en) 2011-08-24
US20110178169A1 (en) 2011-07-21
EP2337560A1 (en) 2011-06-29
AP2011005596A0 (en) 2011-02-28
EP2337560B1 (en) 2014-01-22
BRPI0817954A2 (pt) 2011-01-11
US9115106B2 (en) 2015-08-25
ZA201101706B (en) 2011-11-30
WO2010017613A1 (en) 2010-02-18
BRPI0817954B1 (pt) 2019-08-06

Similar Documents

Publication Publication Date Title
BR112023000770A2 (pt) Inibidor de egfr
CO2022015927A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
CO6612228A2 (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
UY29633A1 (es) Derivados de oxindol
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
BR112014015306A8 (pt) dispositivo de inserção vaginal com segmentos perpendiculares
BR112021023796A2 (pt) Inibidores de moléculas pequenas de quinase indutora de nf-capab
AR095455A1 (es) Derivado fotorreactivo del ácido hialurónico, método para su preparación, derivado del ácido hialurónico con entrecruzamiento tridimensional, método para su preparación y sus usos
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BRPI0510080B8 (pt) combinação farmacêutica e seu uso
BRPI0817954B8 (pt) uso do 5-hidroxi-2-hidroximetil-y-pirona como agente de ativação do macrófago no combate da leishmaniose cutânea
BR112014009506A2 (pt) composição médica de eperisona estabilizada e preparação estabilizada de liberação sustentada contendo eperisona
BR112022004221A2 (pt) Tratamento de hidradenite com inibidores de jak
ES2525451T3 (es) Uso de óxido nitroso inhalado para prevenir el dolor neuropático inducido por sales de platino
SV2009003247A (es) Uso de compuestos de carbamato en la elaboración de medicamentos para el tratamiento de la depresión
BR112014007177A2 (pt) agente antifúngico
MX2018009542A (es) Tratamiento y diagnostico de trastornos inflamatorios.
CO6382113A2 (es) Compuestos quimicos

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF